Search

Your search keyword '"Fanini, Francesca"' showing total 50 results
Start Over Author "Fanini, Francesca"
50 results on '"Fanini, Francesca"'

2. Dendritic cell vaccines as cancer treatment: focus on 13 years of manufacturing and quality control experience in advanced therapy medicinal products

Author

Granato, Anna Maria, Pancisi, Elena, Piccinini, Claudia, Stefanelli, Monica, Pignatta, Sara, Soldati, Valentina, Carloni, Silvia, Fanini, Francesca, Arienti, Chiara, Bulgarelli, Jenny, Tazzari, Marcella, Scarpi, Emanuela, Passardi, Alessandro, Tauceri, Francesca, La Barba, Giuliano, Maimone, Giuseppe, Baravelli, Stefano, de Rosa, Francesco, Ridolfi, Laura, and Petrini, Massimiliano

Published
2024
Full Text
View/download PDF

3. Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.

Author

Vannini, Ivan, Wise, Petra M, Challagundla, Kishore B, Plousiou, Meropi, Raffini, Mirco, Bandini, Erika, Fanini, Francesca, Paliaga, Giorgia, Crawford, Melissa, Ferracin, Manuela, Ivan, Cristina, Fabris, Linda, Davuluri, Ramana V, Guo, Zhiyi, Cortez, Maria Angelica, Zhang, Xinna, Chen, Lu, Zhang, Shuxing, Fernandez-Cymering, Cecilia, Han, Leng, Carloni, Silvia, Salvi, Samanta, Ling, Hui, Murtadha, Mariam, Neviani, Paolo, Gitlitz, Barbara J, Laird-Offringa, Ite A, Nana-Sinkam, Patrick, Negrini, Massimo, Liang, Han, Amadori, Dino, Cimmino, Amelia, Calin, George A, and Fabbri, Muller

Abstract

In the originally published version of this Article, the positions of the final two authors in the author list were inadvertently inverted during the production process. This error has now been corrected in both the PDF and HTML versions of the Article.

Published
2018

4. Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.

Author

Vannini, Ivan, Wise, Petra M, Challagundla, Kishore B, Plousiou, Meropi, Raffini, Mirco, Bandini, Erika, Fanini, Francesca, Paliaga, Giorgia, Crawford, Melissa, Ferracin, Manuela, Ivan, Cristina, Fabris, Linda, Davuluri, Ramana V, Guo, Zhiyi, Cortez, Maria Angelica, Zhang, Xinna, Chen, Lu, Zhang, Shuxing, Fernandez-Cymering, Cecilia, Han, Leng, Carloni, Silvia, Salvi, Samanta, Ling, Hui, Murtadha, Mariam, Neviani, Paolo, Gitlitz, Barbara J, Laird-Offringa, Ite A, Nana-Sinkam, Patrick, Negrini, Massimo, Liang, Han, Amadori, Dino, Cimmino, Amelia, Calin, George A, and Fabbri, Muller

Subjects
Lung, Cell Line, Tumor, Animals, Humans, Mice, Mice, Nude, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Cyclins, MicroRNAs, Xenograft Model Antitumor Assays, Cell Proliferation, Down-Regulation, Gene Expression Regulation, Neoplastic, Up-Regulation, Base Sequence, Conserved Sequence, Genes, Tumor Suppressor, Female, RNA, Long Noncoding, Carcinogenesis, Cell Line, Tumor, Nude, Carcinoma, Non-Small-Cell Lung, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, RNA, Long Noncoding
Abstract

The transcribed ultraconserved regions (T-UCRs) encode long non-coding RNAs implicated in human carcinogenesis. Their mechanisms of action and the factors regulating their expression in cancers are poorly understood. Here we show that high expression of uc.339 correlates with lower survival in 210 non-small cell lung cancer (NSCLC) patients. We provide evidence from cell lines and primary samples that TP53 directly regulates uc.339. We find that transcribed uc.339 is upregulated in archival NSCLC samples, functioning as a decoy RNA for miR-339-3p, -663b-3p, and -95-5p. As a result, Cyclin E2, a direct target of all these microRNAs is upregulated, promoting cancer growth and migration. Finally, we find that modulation of uc.339 affects microRNA expression. However, overexpression or downregulation of these microRNAs causes no significant variations in uc.339 levels, suggesting a type of interaction for uc.339 that we call "entrapping". Our results support a key role for uc.339 in lung cancer.

Published
2017

5. Supplemental Figure 1 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

6. Supplemental Figure 3 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

7. Supplemental Figure 2 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

8. Supplemental Figure 4 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

9. Supplemental Figure 5 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

10. Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center

Author

Pancisi, Elena, primary, Granato, Anna Maria, additional, Scarpi, Emanuela, additional, Ridolfi, Laura, additional, Carloni, Silvia, additional, Moretti, Cinzia, additional, Guidoboni, Massimo, additional, De Rosa, Francesco, additional, Pignatta, Sara, additional, Piccinini, Claudia, additional, Soldati, Valentina, additional, Calabrò, Luana, additional, Framarini, Massimo, additional, Stefanelli, Monica, additional, Bulgarelli, Jenny, additional, Tazzari, Marcella, additional, Fanini, Francesca, additional, and Petrini, Massimiliano, additional

Published
2022
Full Text
View/download PDF

12. Modulation of mismatch repair and genomic stability by miR-155

Author

Valeri, Nicola, Gasparini, Pierluigi, Fabbri, Muller, Braconi, Chiara, Veronese, Angelo, Lovat, Francesca, Adair, Brett, Vannini, Ivan, Fanini, Francesca, Bottoni, Arianna, Costinean, Stefan, Sandhu, Sukhinder K., Nuovo, Gerard J, Alder, Hansjuerg, Gafa, Roberta, Calore, Federica, Ferracin, Manuela, Lanza, Giovanni, Volinia, Stefano, Negrini, Massimo, McIlhatton, Michael A., Amadori, Dino, Fishel, Richard, and Croce, Carlo M.

Published
2010

13. MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS-Mutated Non-Small Cell Lung Cancer

Author

Fanini, Francesca, primary, Bandini, Erika, additional, Plousiou, Meropi, additional, Carloni, Silvia, additional, Wise, Petra, additional, Neviani, Paolo, additional, Murtadha, Mariam, additional, Foca, Flavia, additional, Fabbri, Francesco, additional, Vannini, Ivan, additional, and Fabbri, Muller, additional

Published
2021
Full Text
View/download PDF

14. The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis

Author

Ling, Hui, Pickard, Karen, Ivan, Cristina, Isella, Claudio, Ikuo, Mariko, Mitter, Richard, Spizzo, Riccardo, Bullock, Marc D, Braicu, Cornelia, Pileczki, Valentina, Vincent, Kimberly, Pichler, Martin, Stiegelbauer, Verena, Hoefler, Gerald, Almeida, Maria I, Hsiao, Annie, Zhang, Xinna, Primrose, John N, Packham, Graham K, Liu, Kevin, Bojja, Krishna, Gafà, Roberta, Xiao, Lianchun, Rossi, Simona, Song, Jian H, Vannini, Ivan, Fanini, Francesca, Kopetz, Scott, Zweidler-McKay, Patrick, Wang, Xuemei, Ionescu, Calin, Irimie, Alexandru, Fabbri, Muller, Lanza, Giovanni, Hamilton, Stanley R, Berindan-Neagoe, Ioana, Medico, Enzo, Mirnezami, Alex H, Calin, George A, and Nicoloso, Milena S

Published
2016
Full Text
View/download PDF

15. Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study

Author

Xu, Fei, primary, Zeng, Zhu, additional, Yan, Bing, additional, Fu, Yiqi, additional, Sun, Yilan, additional, Yang, Guangdie, additional, Tu, Lingfang, additional, Watanabe, Satoshi, additional, Jabbour, Salma K., additional, Bravaccini, Sara, additional, Fanini, Francesca, additional, Zhou, Jianying, additional, and Shen, Yihong, additional

Published
2021
Full Text
View/download PDF

17. miR-9-5p as a Regulator of the Androgen Receptor Pathway in Breast Cancer Cell Lines

Author

Bandini, Erika, primary, Fanini, Francesca, additional, Vannini, Ivan, additional, Rossi, Tania, additional, Plousiou, Meropi, additional, Tumedei, Maria Maddalena, additional, Limarzi, Francesco, additional, Maltoni, Roberta, additional, Fabbri, Francesco, additional, Hrelia, Silvana, additional, Cho, William C. S., additional, and Fabbri, Muller, additional

Published
2020
Full Text
View/download PDF

19. Association of a MicroRNA/TP53 Feedback Circuitry With Pathogenesis and Outcome of B-Cell Chronic Lymphocytic Leukemia

Author

Fabbri, Muller, Bottoni, Arianna, Shimizu, Masayoshi, Spizzo, Riccardo, Nicoloso, Milena S., Rossi, Simona, Barbarotto, Elisa, Cimmino, Amelia, Adair, Brett, Wojcik, Sylwia E., Valeri, Nicola, Calore, Federica, Sampath, Deepa, Fanini, Francesca, Vannini, Ivan, Musuraca, Gerardo, Dell’Aquila, Marie, Alder, Hansjuerg, Davuluri, Ramana V., Rassenti, Laura Z., Negrini, Massimo, Nakamura, Tatsuya, Amadori, Dino, Kay, Neil E., Rai, Kanti R., Keating, Michael J., Kipps, Thomas J., Calin, George A., and Croce, Carlo M.

Published
2011
Full Text
View/download PDF

21. Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience

Author

Palleschi, Michela, primary, Maltoni, Roberta, additional, Ravaioli, Sara, additional, Vagheggini, Alessandro, additional, Mannozzi, Francesca, additional, Fanini, Francesca, additional, Pirini, Francesca, additional, Tumedei, Maria, additional, Barzotti, Eleonora, additional, Cecconetto, Lorenzo, additional, Sarti, Samanta, additional, Manunta, Silvia, additional, Possanzini, Paola, additional, Fedeli, Anna, additional, Curcio, Annalisa, additional, Altini, Mattia, additional, De Giorgi, Ugo, additional, Rocca, Andrea, additional, and Bravaccini, Sara, additional

Published
2020
Full Text
View/download PDF

23. ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients

Author

Ravaioli, Sara, primary, Tebaldi, Michela, additional, Fonzi, Eugenio, additional, Angeli, Davide, additional, Mazza, Massimiliano, additional, Nicolini, Fabio, additional, Lucchesi, Alessandro, additional, Fanini, Francesca, additional, Pirini, Francesca, additional, Tumedei, Maria Maddalena, additional, Cerchione, Claudio, additional, Viale, Pierluigi, additional, Sambri, Vittorio, additional, Martinelli, Giovanni, additional, and Bravaccini, Sara, additional

Published
2020
Full Text
View/download PDF

26. Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs (vol 8, 2017)

Author

Vannini, Ivan, Wise, Petra M., Challagundla, Kishore B., Plousiou, Meropi, Raffini, Mirco, Bandini, Erika, Fanini, Francesca, Paliaga, Giorgia, Crawford, Melissa, Ferracin, Manuela, Ivan, Cristina, Fabris, Linda, Davuluri, Ramana V., Guo, Zhiyi, Cortez, Maria Angelica, Zhang, Xinna, Chen, Lu, Zhang, Shuxing, Fernandez-Cymering, Cecilia, Han, Leng, Carloni, Silvia, Salvi, Samanta, Ling, Hui, Murtadha, Mariam, Neviani, Paolo, Gitlitz, Barbara J., Laird-Offringa, Ite A., Nana-Sinkam, Patrick, Negrini, Massimo, Liang, Han, Amadori, Dino, Cimmino, Amelia, Calin, George A., and Fabbri, Muller

Subjects
microRNAs
Abstract

The transcribed ultraconserved regions (T-UCRs) encode long non-coding RNAs implicated in human carcinogenesis. Their mechanisms of action and the factors regulating their expression in cancers are poorly understood. Here we show that high expression of uc.339 correlates with lower survival in 210 non-small cell lung cancer (NSCLC) patients. We provide evidence from cell lines and primary samples that TP53 directly regulates uc.339. We find that transcribed uc.339 is upregulated in archival NSCLC samples, functioning as a decoy RNA for miR-339-3p, -663b-3p, and -95-5p. As a result, Cyclin E2, a direct target of all these microRNAs is upregulated, promoting cancer growth and migration. Finally, we find that modulation of uc.339 affects microRNA expression. However, overexpression or downregulation of these microRNAs causes no significant variations in uc.339 levels, suggesting a type of interaction for uc.339 that we call "entrapping". Our results support a key role for uc.339 in lung cancer.

Published
2018

29. A miR-155/TP53 regulatory feedback loop involved in resistance to therapy in lung cancer and leukemia

Author

Van Roosbroeck, Katrien, Fanini, Francesca, Setoyama, Tetsuro, Ivan, Cristina, Rodriguez-Aguayo, Cristian, Vannini, Ivan, Redis, Roxana S., D’Abundo, Lucilla, Zhang, Xinna, Xiao, Lianchun, Nicoloso, Milena S., Rossi, Simona, Gonzalez-Villasana, Vianey, Rupaimoole, Rajesha, Ferracin, Manuela, Morabito, Fortunato, Neri, Antonino, Ruvolo, Peter P., Ruvolo, Vivian R., Pecot, Chad V., Amadori, Dino, Abruzzo, Lynne, Calin, Steliana, Wang, Xuemei, You, M. James, Ferrajoli, Alessandra, Orlowski, Robert, Plunkett, William, Davuluri, Ramana V., Berindan-Neagoe, Ioana, Negrini, Massimo, Wistuba, Ignacio I., Kantarjian, Hagop M., Sood, Anil K., Lopez-Berestein, Gabriel, Keating, Michael J., Fabbri, Muller, and Calin, George A.

Subjects
Gene Expression Regulation, Neoplastic, Mice, MicroRNAs, Lung Neoplasms, Drug Resistance, Neoplasm, Cell Line, Tumor, Animals, Antagomirs, Humans, Cisplatin, Tumor Suppressor Protein p53, Article
Published
2016

33. Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, additional, Setoyama, Tetsuro, additional, Ivan, Cristina, additional, Rodriguez-Aguayo, Cristian, additional, Fuentes-Mattei, Enrique, additional, Xiao, Lianchun, additional, Vannini, Ivan, additional, Redis, Roxana S., additional, D'Abundo, Lucilla, additional, Zhang, Xinna, additional, Nicoloso, Milena S., additional, Rossi, Simona, additional, Gonzalez-Villasana, Vianey, additional, Rupaimoole, Rajesha, additional, Ferracin, Manuela, additional, Morabito, Fortunato, additional, Neri, Antonino, additional, Ruvolo, Peter P., additional, Ruvolo, Vivian R., additional, Pecot, Chad V., additional, Amadori, Dino, additional, Abruzzo, Lynne, additional, Calin, Steliana, additional, Wang, Xuemei, additional, You, M. James, additional, Ferrajoli, Alessandra, additional, Orlowski, Robert, additional, Plunkett, William, additional, Lichtenberg, Tara M., additional, Davuluri, Ramana V., additional, Berindan-Neagoe, Ioana, additional, Negrini, Massimo, additional, Wistuba, Ignacio I., additional, Kantarjian, Hagop M., additional, Sood, Anil K., additional, Lopez-Berestein, Gabriel, additional, Keating, Michael J., additional, Fabbri, Muller, additional, and Calin, George A., additional

Published
2017
Full Text
View/download PDF

35. A Dendritic Cell (DC) microRNA signature predicts clinical outcome in Melanoma Patients treated with DC vaccine

Author

Granato Anna, Guidoboni Massimo, Bandini Erika, Ridolfi Laura, Fiammenghi Laura, Pancisi Elena, Petrini Massimiliano, Fanini Francesca, Ancarani Valentina, and Fabbri Muller

Subjects
Dc vaccine, business.industry, Melanoma, Immunology, microRNA, medicine, Cancer research, Immunology and Allergy, Dendritic cell, medicine.disease, business
Published
2013
Full Text
View/download PDF

36. Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy

Author

Challagundla, Kishore B., primary, Wise, Petra M., additional, Neviani, Paolo, additional, Chava, Haritha, additional, Murtadha, Mariam, additional, Xu, Tong, additional, Kennedy, Rebekah, additional, Ivan, Cristina, additional, Zhang, Xinna, additional, Vannini, Ivan, additional, Fanini, Francesca, additional, Amadori, Dino, additional, Calin, George A., additional, Hadjidaniel, Michael, additional, Shimada, Hiroyuki, additional, Jong, Ambrose, additional, Seeger, Robert C., additional, Asgharzadeh, Shahab, additional, Goldkorn, Amir, additional, and Fabbri, Muller, additional

Published
2015
Full Text
View/download PDF

37. The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis

Author

Ling, Hui, primary, Pickard, Karen, additional, Ivan, Cristina, additional, Isella, Claudio, additional, Ikuo, Mariko, additional, Mitter, Richard, additional, Spizzo, Riccardo, additional, Bullock, Marc D, additional, Braicu, Cornelia, additional, Pileczki, Valentina, additional, Vincent, Kimberly, additional, Pichler, Martin, additional, Stiegelbauer, Verena, additional, Hoefler, Gerald, additional, Almeida, Maria I, additional, Hsiao, Annie, additional, Zhang, Xinna, additional, Primrose, John N, additional, Packham, Graham K, additional, Liu, Kevin, additional, Bojja, Krishna, additional, Gafà, Roberta, additional, Xiao, Lianchun, additional, Rossi, Simona, additional, Song, Jian H, additional, Vannini, Ivan, additional, Fanini, Francesca, additional, Kopetz, Scott, additional, Zweidler-McKay, Patrick, additional, Wang, Xuemei, additional, Ionescu, Calin, additional, Irimie, Alexandru, additional, Fabbri, Muller, additional, Lanza, Giovanni, additional, Hamilton, Stanley R, additional, Berindan-Neagoe, Ioana, additional, Medico, Enzo, additional, Mirnezami, Alex H, additional, Calin, George A, additional, and Nicoloso, Milena S, additional

Published
2015
Full Text
View/download PDF

38. MiR-30 Family Potentially Targeting PI3K-SIAH2 Predicted Interaction Network Represents a Novel Putative Theranostic Panel in Non-small Cell Lung Cancer.

Author

Chan, Lawrence W. C., Fengfeng Wang, Fei Meng, Lili Wang, Sze Chuen Cesar Wong, Au, Joseph S. K., Sijun Yang, Cho, William C. S., Fanini, Francesca, and Bowen, Timothy

Subjects
LUNG cancer, PROTEIN-tyrosine kinase inhibitors, ERLOTINIB, THERAPEUTICS
Abstract

Non-small cell lung cancer (NSCLC) comprises about 84% of all lung cancers. Many treatment options are available but the survival rate is still very low due to drug resistance. It has been found that phosphoinositide-3-kinase (PI3K) affects sensitivity to tyrosine kinase inhibitors (TKIs), including gefitinib and erlotinib. Expression level of seven in absentia homolog 2 (SIAH2), an E3 ubiquitin-protein ligase, is upregulated in NSCLC and correlated with tumor grade. However, the relationship between PI3K and SIAH2 remains unclear and therefore it is not known whether they can act as treatment co-targets and theranostic dual markers for overcoming TKI resistance. It is worthy to note that PI3K and SIAH2 are potentially regulated by a common group of microRNAs in miR-30 family. Our bioinformatics analyses showed upregulated SIAH2 expression in NSCLC based on mass spectrometry data, explored its indirect interaction with PI3K and predicted their targeting microRNAs in common. We have also explored the potential role of miR-30 family in the modulation of PI3K-SIAH2 interaction in NSCLC. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

43. Abstract LB-347: A microRNA signature harbors prognostic implications in clear cell renal carcinoma (ccRC)

Author

Fanini, Francesca, primary, Vannini, Ivan, additional, Fernandez-Cymering, Cecilia, additional, Volinia, Stefano, additional, Ridolfi, Laura, additional, Palatini, Jeff, additional, Casadio, Valentina, additional, Arienti, Chiara, additional, Ulivi, Paola, additional, Zoli, Wainer, additional, Amadori, Dino, additional, Croce, Carlo M., additional, and Fabbri, Muller, additional

Published
2011
Full Text
View/download PDF

46. ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients

Author

Eugenio Fonzi, Fabio Nicolini, Vittorio Sambri, Francesca Fanini, Massimiliano Mazza, Michela Tebaldi, Claudio Cerchione, Maria Maddalena Tumedei, Sara Ravaioli, Sara Bravaccini, Pierluigi Viale, Alessandro Lucchesi, Davide Angeli, Giovanni Martinelli, Francesca Pirini, Ravaioli, Sara, Tebaldi, Michela, Fonzi, Eugenio, Angeli, Davide, Mazza, Massimiliano, Nicolini, Fabio, Lucchesi, Alessandro, Fanini, Francesca, Pirini, Francesca, Tumedei, Maria Maddalena, Cerchione, Claudio, Viale, Pierluigi, Sambri, Vittorio, Martinelli, Giovanni, and Bravaccini, Sara

Subjects
0301 basic medicine, Male, ACE2, lcsh:Medicine, Germline, 0302 clinical medicine, Gene Frequency, Neoplasms, Databases, Genetic, Young adult, African Continental Ancestry Group, education.field_of_study, Incidence, Serine Endopeptidases, Middle Aged, Serine Endopeptidase, Special Collection on Cell Transplantation and COVID-19, 030220 oncology & carcinogenesis, Spike Glycoprotein, Coronavirus, Original Article, Female, Angiotensin-Converting Enzyme 2, Coronavirus Infections, Case-Control Studie, Human, Adult, Population, Pneumonia, Viral, Biomedical Engineering, Black People, Biology, Peptidyl-Dipeptidase A, TMPRSS2, 03 medical and health sciences, Betacoronavirus, Young Adult, Genetic variation, Genetic predisposition, Humans, Genetic Predisposition to Disease, education, Allele frequency, Pandemics, Transplantation, Binding Sites, Betacoronaviru, Pandemic, SARS-CoV-2, Coronavirus Infection, individual susceptibility, lcsh:R, Case-control study, Binding Site, COVID-19, Genetic Variation, Cell Biology, 030104 developmental biology, Case-Control Studies, Immunology, Neoplasm, Spike Glycoprotein, Coronaviru
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. One open question is whether genetics could influence the severity of symptoms. Considering the limited data on cancer patients, we analyzed public data repositories limited to investigate angiotensin-converting enzyme 2 (ACE2) and the transmembrane serine protease 2 (TMPRSS2) expressions and genetic variants to identify the basis of individual susceptibility to SARS-CoV-2. Gene expression and variant data were retrieved from Tissue Cancer Genome Atlas, Genotype-Tissue Expression, and gnomAD. Differences in gene expression were tested with Mann-Whitney U-test. Allele frequencies of germline variants were explored in different ethnicities, with a special focus on ACE2 variants located in the binding site to SARS-CoV-2 spike protein. The analysis of ACE2 and TMPRSS2 expressions in healthy tissues showed a higher expression in the age class 20 to 59 years (false discovery rate [FDR] < 0.0001) regardless of gender. ACE2 and TMPRSS2 were more expressed in tumors from males than females (both FDR < 0.0001) and, opposite to the regulation in tissues from healthy individuals, more expressed in elderly patients (FDR = 0.005; FDR < 0.0001, respectively). ACE2 and TMPRSS2 expressions were higher in cancers of elderly patients compared with healthy individuals (FDR < 0.0001). Variants were present at low frequency (range 0% to 3%) and among those with the highest frequency, the variant S19P belongs to the SARS-CoV-2 spike protein binding site and it was exclusively present in Africans with a frequency of 0.2%. The mechanisms of ACE2 and TMPRSS2 regulation could be targeted for preventive and therapeutic purposes in the whole population and especially in cancer patients. Further studies are needed to show a direct correlation of ACE2 and TMPRSS2 expressions in cancer patients and the incidence of COVID-19.

Published
2020

47. Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience

Author

Alessandro Vagheggini, Roberta Maltoni, Michela Palleschi, Paola Possanzini, Eleonora Barzotti, Anna Fedeli, Sara Bravaccini, Silvia Manunta, Andrea Rocca, Lorenzo Cecconetto, Mattia Altini, Francesca Mannozzi, Annalisa Curcio, Sara Ravaioli, Francesca Pirini, Samanta Sarti, Ugo De Giorgi, Maria Maddalena Tumedei, Francesca Fanini, Palleschi, Michela, Maltoni, Roberta, Ravaioli, Sara, Vagheggini, Alessandro, Mannozzi, Francesca, Fanini, Francesca, Pirini, Francesca, Tumedei, Maria Maddalena, Barzotti, Eleonora, Cecconetto, Lorenzo, Sarti, Samanta, Manunta, Silvia, Possanzini, Paola, Fedeli, Anna, Curcio, Annalisa, Altini, Mattia, De Giorgi, Ugo, Rocca, Andrea, and Bravaccini, Sara

Subjects
0301 basic medicine, medicine.medical_specialty, Clinical Biochemistry, Estrogen receptor, Palbociclib, Gastroenterology, CDK4/6 inhibitor, Article, PR, 03 medical and health sciences, CDK4/6 inhibitors, 0302 clinical medicine, Internal medicine, Progesterone receptor, medicine, advanced breast cancer, lcsh:R5-920, Univariate analysis, business.industry, Hazard ratio, Cancer, medicine.disease, Ki67, Confidence interval, 030104 developmental biology, 030220 oncology & carcinogenesis, Immunohistochemistry, lcsh:Medicine (General), business
Abstract

CDK4/6 inhibitors (CDK4/6i) are recommended in patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer (ABC). Up to now, no prognostic biomarkers have been identified in this setting. We retrospectively analyzed the expression of progesterone receptor (PR) and Ki67, assessed by immunohistochemistry, in 71 ABC patients treated with CDK4/6i and analyzed the impact of these markers on progression-free survival (PFS). The majority of patients 63/71 (88.7%) received palbociclib, 4 (5.6%) received ribociclib, and 4 (5.6%) received abemaciclib. A higher median value of Ki67 was observed in cases undergoing second-line treatment (p = 0.047), whereas the luminal B subtype was more prevalent (p = 0.005). In the univariate analysis of the first-line setting, luminal A subtype showed a trend towards a correlation with a longer PFS (p = 0.053). A higher continuous Ki67 value led to a significantly shorter PFS. When the interaction between pathological characteristics and line of treatment was considered, luminal B subtype showed a significantly (p = 0.043) worse outcome (Hazard Ratio (HR) 2.84, 1.03&ndash, 7.82 95% Confidence Interval (CI)). PFS in patients undergoing endocrine therapy plus CDK4/6i was inversely correlated with Ki67 expression but not with PR, suggesting that tumor proliferation has a greater impact on cell cycle inhibitors combined with endocrine therapy than PR expression.

Published
2020

48. Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Alessandra Ferrajoli, Katrien Van Roosbroeck, Massimo Negrini, Ioana Berindan-Neagoe, Dino Amadori, Hagop M. Kantarjian, Peter P. Ruvolo, Manuela Ferracin, Roxana S. Redis, Lianchun Xiao, Xuemei Wang, George A. Calin, Simona Rossi, Ivan Vannini, Antonino Neri, Robert Z. Orlowski, Steliana Calin, Vivian Ruvolo, Fortunato Morabito, Vianey Gonzalez-Villasana, Tara M. Lichtenberg, Gabriel Lopez-Berestein, Lynne V. Abruzzo, Ramana V. Davuluri, Michael J. Keating, Anil K. Sood, Rajesha Rupaimoole, M. James You, William Plunkett, Francesca Fanini, Chad V. Pecot, Tetsuro Setoyama, Xinna Zhang, Ignacio I. Wistuba, Muller Fabbri, Lucilla D’Abundo, Milena S. Nicoloso, Cristina Ivan, Enrique Fuentes-Mattei, Cristian Rodriguez-Aguayo, Van Roosbroeck, Katrien, Fanini, Francesca, Setoyama, Tetsuro, Ivan, Cristina, Rodriguez-Aguayo, Cristian, Fuentes-Mattei, Enrique, Xiao, Lianchun, Vannini, Ivan, Redis, Roxana S., D'Abundo, Lucilla, Zhang, Xinna, Nicoloso, Milena S., Rossi, Simona, Gonzalez-Villasana, Vianey, Rupaimoole, Rajesha, Ferracin, Manuela, Morabito, Fortunato, Neri, Antonino, Ruvolo, Peter P., Ruvolo, Vivian R., Pecot, Chad V., Amadori, Dino, Abruzzo, Lynne, Calin, Steliana, Wang, Xuemei, You, M. Jame, Ferrajoli, Alessandra, Orlowski, Robert, Plunkett, William, Lichtenberg, Tara M., Davuluri, Ramana V., Berindan-Neagoe, Ioana, Negrini, Massimo, Wistuba, Ignacio I., Kantarjian, Hagop M., Sood, Anil K., Lopez-Berestein, Gabriel, Keating, Michael J., Fabbri, Muller, and Calin, George A.

Subjects
0301 basic medicine, Cancer Research, therapy resistance, medicine.medical_treatment, Chronic lymphocytic leukemia, chemotherapy, therapy resistance, miR-155, Socio-culturale, Drug resistance, Gene mutation, chemotherapy, miR-155, 03 medical and health sciences, 0302 clinical medicine, In vivo, medicine, Doxorubicin, Lung cancer, Chemotherapy, microRNA, business.industry, Cancer, medicine.disease, 3. Good health, lung cancer, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Immunology, Cancer research, business, medicine.drug
Abstract

Purpose: The oncogenic miR-155 is upregulated in many human cancers, and its expression is increased in more aggressive and therapy-resistant tumors, but the molecular mechanisms underlying miR-155-induced therapy resistance are not fully understood. The main objectives of this study were to determine the role of miR-155 in resistance to chemotherapy and to evaluate anti-miR-155 treatment to chemosensitize tumors. Experimental Design: We performed in vitro studies on cell lines to investigate the role of miR-155 in therapy resistance. To assess the effects of miR-155 inhibition on chemoresistance, we used an in vivo orthotopic lung cancer model of athymic nude mice, which we treated with anti-miR-155 alone or in combination with chemotherapy. To analyze the association of miR-155 expression and the combination of miR-155 and TP53 expression with cancer survival, we studied 956 patients with lung cancer, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. Results: We demonstrate that miR-155 induces resistance to multiple chemotherapeutic agents in vitro, and that downregulation of miR-155 successfully resensitizes tumors to chemotherapy in vivo. We show that anti-miR-155-DOPC can be considered non-toxic in vivo. We further demonstrate that miR-155 and TP53 are linked in a negative feedback mechanism and that a combination of high expression of miR-155 and low expression of TP53 is significantly associated with shorter survival in lung cancer. Conclusions: Our findings support the existence of an miR-155/TP53 feedback loop, which is involved in resistance to chemotherapy and which can be specifically targeted to overcome drug resistance, an important cause of cancer-related death. Clin Cancer Res; 23(11); 2891–904. ©2016 AACR.

Published
2017

49. Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results

Author

Paola Rosetti, Claudio Dazzi, Flavia Foca, Andrea Casadei Gardini, Francesca Fanini, Martina Valgiusti, Maurizio Marangolo, Silvia Ruscelli, Alessandro Passardi, Livia Turci, Passardi, Alessandro, Fanini, Francesca, Turci, Livia, Foca, Flavia, Rosetti, Paola, Ruscelli, Silvia, Casadei Gardini, Andrea, Valgiusti, Martina, Dazzi, Claudio, and Marangolo, Maurizio

Subjects
0301 basic medicine, Oncology, Male, Cancer Research, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Phases of clinical research, Pemetrexed, Neutropenia, Vinorelbine, Deoxycytidine, Disease-Free Survival, Drug Administration Schedule, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Cell Line, Tumor, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, Neoplasm Metastasis, Infusions, Intravenous, Aged, Performance status, business.industry, Standard treatment, Clinical Trial Results, Middle Aged, medicine.disease, Gemcitabine, Carboplatin, 030104 developmental biology, chemistry, 030220 oncology & carcinogenesis, Disease Progression, Female, business, Colorectal Neoplasms, medicine.drug
Abstract

Lessons Learned Difficulties in translating in vitro results into clinical practice are inevitable. Further efforts to verify the efficacy of alternative schedules of pemetrexed in solid tumors are encouraged. Background We investigated the cytotoxic activity of pemetrexed in combination with several drugs (gemcitabine, carboplatin, vinorelbine, and mitomycin C) using different exposure schedules in three colon cancer cell lines. The best results were obtained with the following schedule: a prolonged pemetrexed exposure followed by a 48-hour wash-out and then gemcitabine. This combination was then advanced to a phase II clinical trial. Methods Patients with metastatic colorectal cancer in progression after standard treatment were included in the study. Adequate bone marrow reserve, normal hepatic and renal function, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2 were required. Treatment consisted of an 8-hour intravenous infusion of pemetrexed 150 mg/m2 on day 1 and a 30-minute intravenous infusion of gemcitabine 1,000 mg/m2 on day 3 of each cycle, repeated every 14 days. Results Fourteen patients were enrolled onto the study (first step). No objective responses were seen, and evidence of stable disease was observed in only one of the 12 evaluable patients. The most important grade 3–4 side effects were hematological toxicity (neutropenia 64.2%, thrombocytopenia 71.4%, anemia 28.7%), fatigue (50.0%), and stomatitis (21.5%). Median overall survival and time to progression were 5.8 months (95% confidence interval [CI]: 3.9–7.1) and 2.1 months (95% CI: 1.7–2.8), respectively. Conclusion The experimental pemetrexed-gemcitabine combination proved to be inactive and moderately toxic.

Published
2017

50. Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy.

Author

Challagundla KB, Wise PM, Neviani P, Chava H, Murtadha M, Xu T, Kennedy R, Ivan C, Zhang X, Vannini I, Fanini F, Amadori D, Calin GA, Hadjidaniel M, Shimada H, Jong A, Seeger RC, Asgharzadeh S, Goldkorn A, and Fabbri M

Subjects
Antineoplastic Agents pharmacology, Cell Communication, Cisplatin pharmacology, Coculture Techniques, Gene Expression Regulation, Neoplastic, Heterografts, Humans, NF-kappa B metabolism, Neuroblastoma metabolism, Real-Time Polymerase Chain Reaction, Receptor Cross-Talk, Shelterin Complex, Telomere-Binding Proteins metabolism, Toll-Like Receptor 8 metabolism, Tumor Microenvironment, Drug Resistance, Neoplasm, Exosomes metabolism, MicroRNAs metabolism, Monocytes metabolism, Neuroblastoma drug therapy, Signal Transduction drug effects
Abstract

Background: How exosomic microRNAs (miRNAs) contribute to the development of drug resistance in the context of the tumor microenvironment has not been previously described in neuroblastoma (NBL)., Methods: Coculture experiments were performed to assess exosomic transfer of miR-21 from NBL cells to human monocytes and miR-155 from human monocytes to NBL cells. Luciferase reporter assays were performed to assess miR-155 targeting of TERF1 in NBL cells. Tumor growth was measured in NBL xenografts treated with Cisplatin and peritumoral exosomic miR-155 (n = 6 mice per group) CD163, miR-155, and TERF1 levels were assessed in 20 NBL primary tissues by Human Exon Arrays and quantitative real-time polymerase chain reaction. Student's t test was used to evaluate the differences between treatment groups. All statistical tests were two-sided., Results: miR-21 mean fold change (f.c.) was 12.08±0.30 (P < .001) in human monocytes treated with NBL derived exosomes for 48 hours, and miR-155 mean f.c. was 4.51±0.25 (P < .001) in NBL cells cocultured with human monocytes for 48 hours. TERF1 mean luciferase activity in miR-155 transfected NBL cells normalized to scrambled was 0.36 ± 0.05 (P <.001). Mean tumor volumes in Dotap-miR-155 compared with Dotap-scrambled were 322.80±120mm(3) and 76.00±39.3mm(3), P = .002 at day 24, respectively. Patients with high CD163 infiltrating NBLs had statistically significantly higher intratumoral levels of miR-155 (P = .04) and lower levels of TERF1 mRNA (P = .02)., Conclusions: These data indicate a unique role of exosomic miR-21 and miR-155 in the cross-talk between NBL cells and human monocytes in the resistance to chemotherapy, through a novel exosomic miR-21/TLR8-NF-кB/exosomic miR-155/TERF1 signaling pathway., (© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results